← Back to Search

Cancer Vaccine

ALG.APV-527 for Advanced Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Aptevo Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through completion of both dose escalation and dose expansion ( approx 42 months)
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug, ALG.APV-527, in adults with advanced solid tumors who have no other effective treatments. The drug is given through an IV to find the safest dose. Researchers aim to see if the drug is safe and can help shrink tumors.

Who is the study for?
Adults with advanced solid tumors that have failed standard treatments or for whom no effective therapy exists. They must be over 18, have a life expectancy of at least 3 months, and agree to use effective birth control. Specific cancers include NSCLC, breast cancer, ovarian cancer among others. Participants need adequate organ function and measurable lesions by CT/MRI.
What is being tested?
The trial is testing ALG.APV-527 in patients with advanced solid tumors likely to express the 5T4 antigen. It's an open-label study with two parts: dose escalation (about 36 patients) and dose expansion (about 20 patients), focusing on safety and optimal dosing.
What are the potential side effects?
As this is a first-in-human study for ALG.APV-527, specific side effects are not yet known but may include typical reactions related to immune therapies such as fatigue, infusion-related reactions, autoimmune-like symptoms or exacerbation of underlying conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through completion of both dose escalation and dose expansion ( approx 42 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and through completion of both dose escalation and dose expansion ( approx 42 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with dose-limiting toxicities (DLTs)
Overall Response Rate
Secondary study objectives
Pharmacokinetic measure- Area under the plasma concentration versus time curve (AUC)
Pharmacokinetic measure- Peak Plasma Concentration (Cmax)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ALG.APV-527Experimental Treatment1 Intervention
Part 1 Dose Escalation using ALG.APV-527 doses with a starting dose of 0.1 mg/kg and projected 6 dose cohorts will be explored to determine the MTD and/or the RP2D. Part 1 consists of a 3 + 3 dose-escalation examination of ALG.APV-527 single agent therapy in adult patients with RECIST Version1.1-measurable advanced solid tumors. Part 2 Dose Expansion with ALG.APV-527 based on RP2D determined during Dose Escalation.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for solid tumors, particularly targeted therapies and immunotherapies, work by identifying and attacking specific antigens or proteins expressed on cancer cells. For example, ALG.APV-527 targets the 5T4 antigen, which is often present on advanced solid tumors. These therapies enhance the immune system's ability to recognize and destroy cancer cells while minimizing damage to normal cells. This targeted approach is crucial for patients with solid tumors as it offers a more effective and less toxic treatment option compared to traditional chemotherapy, potentially leading to better outcomes and improved quality of life.
Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer.Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.

Find a Location

Who is running the clinical trial?

Aptevo TherapeuticsLead Sponsor
8 Previous Clinical Trials
433 Total Patients Enrolled
Alligator Bioscience ABIndustry Sponsor
4 Previous Clinical Trials
178 Total Patients Enrolled

Media Library

ALG.APV-527 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05934539 — Phase 1 & 2
Solid Tumors Research Study Groups: ALG.APV-527
Solid Tumors Clinical Trial 2023: ALG.APV-527 Highlights & Side Effects. Trial Name: NCT05934539 — Phase 1 & 2
ALG.APV-527 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05934539 — Phase 1 & 2
~20 spots leftby Oct 2025